MRK241220C125000
- 0.01
- 0.000.00%
Merck & Co Newsroom
The 15.92% Average Gain in Inauguration Year: Will Trump's Second Term Echo the Trend?
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Brand Prescription Drugs to Rise an Average 4.5% in 2025
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
These Are the Best and Worst Stocks This Year
Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Express News | UK's Mhra: Sotatercept Approved to Treat Adult Patients With Pulmonary Arterial Hypertension (Pah)
Merck & Co., Inc. (NYSE:MRK) Is a Favorite Amongst Institutional Investors Who Own 79%
This Biotech Is One of the S&P 500's Worst Performers. It Looks Too Cheap.
Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024?
Takeda-backed Ascentage Pharma Files for $100M IPO
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now